SCHEMBL1706854

SCHEMBL1706854

O=c1ccc2cc(-c3ccccc3O)c(-c3ccccc3O)cc2o1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 6/20 0.69
CA9 Q16790 9/20 0.62
CA12 O43570 7/20 0.62
MCL1 Q07820 6/20 0.62
AKR1B1 P15121 4/20 0.62
KDM4E B2RXH2 3/20 0.62
ALDH1A1 P00352 3/20 0.62
GLA P06280 3/20 0.62
GAA P10253 3/20 0.62
HPGD P15428 3/20 0.62
CASP1 P29466 3/20 0.62
CASP7 P55210 3/20 0.62
HSD17B10 Q99714 3/20 0.62
ERAP1 Q9NZ08 3/20 0.62
CYP1A2 P05177 2/20 0.62
HIF1A Q16665 2/20 0.62
LMNA P02545 2/20 0.62
BCHE P06276 1/20 0.62
CYP3A4 P08684 1/20 0.62
MAPT P10636 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18788576 0.82 PGR (0.52) PGRCA9CA12MCL1AKR1B1
SCHEMBL30108452 0.79 MIF (0.74) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL1706856 0.79 MIF (0.74) KDM4EALDH1A1GLAGAAHPGD
Esculetin SCHEMBL24641 0.77 CA9 (1.00) PGRCA9CA12MCL1AKR1B1
Esculetin SCHEMBL29569228 0.77 CA9 (1.00) PGRCA9CA12MCL1AKR1B1
Esculetin SCHEMBL6867015 0.77 CA9 (1.00) PGRCA9CA12MCL1AKR1B1
Esculetin SCHEMBL8718947 0.76 CA9 (0.79) PGRCA9CA12MCL1AKR1B1
SCHEMBL2355820 0.76 LMNA (0.77) CA9CA12AKR1B1KDM4EALDH1A1
SCHEMBL30108485 0.76 LMNA (0.77) CA9CA12AKR1B1KDM4EALDH1A1
Esculetin SCHEMBL1736697 0.76 CA9 (0.96) PGRCA9CA12MCL1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828407-B2 Water soluble and activable phenolic derivatives with dermocosmetic and therapeutic applications and process for preparing said derivatives LIBRAGEN (FR) 2017-11-28 US claimed
US-20140088030-A1 WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES LIBRAGEN (FR) 2014-03-27 US claimed
EP-2027279-B1 Phenolic compounds with cosmetic and therapeutic applications LIBRAGEN (FR) 2012-04-18 EP claimed
EP-2027279-A2 WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES Libragen (FR) 2009-02-25 EP claimed
WO-2007144368-A2 WATER SOLUBLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS LIBRAGEN (FR) 2007-12-21 WO claimed
CN-105838758-B Water-soluble phenolic derivatives for cosmetic and therapeutic applications on the skin 利布莱根公司 2020-03-06 CN disclosed
US-9828407-B2 Water soluble and activable phenolic derivatives with dermocosmetic and therapeutic applications and process for preparing said derivatives LIBRAGEN (FR) 2017-11-28 US disclosed
CN-105838758-A Water soluble phenolics derivatives with dermocosmetic and therapeutic applications 利布莱根公司 2016-08-10 CN disclosed
CN-101611148-B Water-soluble phenolic derivatives for cosmetic and therapeutic applications on the skin LIBRAGEN (FR) 2016-03-16 CN disclosed
US-20140088030-A1 WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES LIBRAGEN (FR) 2014-03-27 US disclosed
US-20090233876-A1 Water Soluble and Activable Phenolics Derivatives with Dermocosmetic and Therapeutic Applications and Process for Preparing Said Derivatives LIBRAGEN (FR) 2009-09-17 US disclosed
EP-2027279-A2 WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES Libragen (FR) 2009-02-25 EP disclosed
WO-2007144368-A2 WATER SOLUBLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS LIBRAGEN (FR) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233876-A1 Water Soluble and Activable Phenolics Derivatives with Dermocosmetic and Therapeutic Applications and Process for Preparing Said Derivatives UGGT1, TYR, LCT PGR 2966/4885CA9 3628/4885CA12 4097/4885
US-20140088030-A1 WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES UGGT1, TYR, G6PD PGR 2573/4885CA9 3760/4885CA12 4200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.